DDrare: Database of Drug Development for Rare Diseases

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-flumazenil; 18F-FTC-146; ACIDUM ASCORBICUM D6; AF056; AFQ056; AZD7325; AZD7325 (High-Dose); AZD7325 (Low-Dose); Acamprosate; Acetate; Acidum ascorbicum; Alpha-tocopherol; Ampalex; Arbaclofen; Aripiprazole; Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E); Ascorbic acid; BPN14770; CBD; CCD 1042, MD 9150000, Mepalon 1042, SPT316; CX516; CX516 (Ampalex®); Donepezil; EGCG; EGCG FontUp; Flumazenil; Fluoxetin; GANAXOLONE; Gaboxadol; Ganaxolone; Lovastatin; Lovastatin, then Minocycline/Lovastatin; MG01CI extended-release tablet; MGlu5 antagonist; Mavoglurant; Metformin; Methylphenidate; Methylphenidate, fluoxetin, risperidone; Minocycline; Minocycline hydrochloride; Minocycline, then Minocycline/Lovastatin; NNZ-2566; NPL-2009; OV101; OV101 (gaboxadol); Other: Biological samples; Other: Cognitive training; Other: Language Intervention; Other: MRI; Oxytocin; Oxytocin 24IU; Oxytocin 48IU; RO4917523; RO4917523 0.5 mg; RO4917523 1.5 mg; Riluzole; Risperidone; Ro 491-7523/F18; Ro 491-7523/F19; STX107; STX209; Sertraline; Sugar pill; TOCOPHERYL ACETATE; Tocopherol; Tocopheryl acetate; Vitamin C; Vitamin C 10mg/Kg Vitamin E 10 mg/Kg; Vitamin E; ZYN002 - CBD Transdermal Gel; [18F]FPEB; [18F]FPEB PET imaging; [18F]flumazenil

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02680379 (ClinicalTrials.gov)	March 2016	25/1/2016	Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome	A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)	Fragile X Syndrome	Drug: Minocycline , then Minocycline/Lovastatin;Drug: Lovastatin , then Minocycline/Lovastatin	Université de Sherbrooke	FRAXA Research Foundation	Completed	8 Years	45 Years	All	22	Phase 2	Canada
2	NCT02642653 (ClinicalTrials.gov)	January 2016	21/12/2015	Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome	Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome	Fragile X Syndrome;Genetic Diseases	Drug: Lovastatin;Other: Placebo	University of California, Davis	NULL	Completed	10 Years	17 Years	All	30	Phase 4	United States
3	NCT02998151 (ClinicalTrials.gov)	January 2016	1/12/2016	Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome	Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome	Fragile X Syndrome	Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo	Children's Hospital Medical Center, Cincinnati	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Enrolling by invitation	15 Years	55 Years	All	36	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02680379
(ClinicalTrials.gov)

March 2016

25/1/2016

Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome

A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)

Fragile X Syndrome

Drug: Minocycline , then Minocycline/Lovastatin;Drug: Lovastatin , then Minocycline/Lovastatin

Université de Sherbrooke

FRAXA Research Foundation

Completed

8 Years

45 Years

All

Phase 2

Canada

NCT02642653
(ClinicalTrials.gov)

January 2016

21/12/2015

Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome

Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome

Fragile X Syndrome;Genetic Diseases

Drug: Lovastatin;Other: Placebo

University of California, Davis

NULL

Completed

10 Years

17 Years

All

Phase 4

United States

NCT02998151
(ClinicalTrials.gov)

January 2016

1/12/2016

Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome

Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome

Fragile X Syndrome

Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo

Children's Hospital Medical Center, Cincinnati

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Enrolling by invitation

15 Years

55 Years

All

Phase 2

United States